Trial · NCT02850406
Adverse event totals24
The totals the trial posted for each group.
1 to 20 of 24
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 0 | 7 |
| Total, all-cause mortality | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 0 | 6 |
| Total, all-cause mortality | Part B: Voxelotor 900 mg QD | 0 | 25 |
| Total, all-cause mortality | Part B: Voxelotor 1500 mg QD | 0 | 15 |
| Total, all-cause mortality | Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD | 0 | 51 |
| Total, all-cause mortality | Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD | 0 | 11 |
| Total, all-cause mortality | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | 0 | 9 |
| Total, all-cause mortality | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | 0 | 23 |
| Total, other adverse events | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 6 | 7 |
| Total, other adverse events | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 3 | 6 |
| Total, other adverse events | Part B: Voxelotor 900 mg QD | 22 | 25 |
| Total, other adverse events | Part B: Voxelotor 1500 mg QD | 15 | 15 |
| Total, other adverse events | Part C: Participants Aged 4 to 11 Years: Voxelotor 1500 mg QD | 46 | 51 |
| Total, other adverse events | Part C: Participants Aged 12 to 17 Years: Voxelotor 1500 mg QD | 11 | 11 |
| Total, other adverse events | Part D: Participants Aged 6 Months to <2 Years: Voxelotor 1500 mg QD | 9 | 9 |
| Total, other adverse events | Part D: Participants Aged 2 to <4 Years: Voxelotor 1500 mg QD | 21 | 23 |
| Total, serious adverse events | Part A: Participants Aged 12 to 17 Years: Voxelotor 600 mg | 1 | 7 |
| Total, serious adverse events | Part A: Participants Aged 6 to 11 Years: Voxelotor 600 mg | 0 | 6 |
| Total, serious adverse events | Part B: Voxelotor 900 mg QD | 12 | 25 |
| Total, serious adverse events | Part B: Voxelotor 1500 mg QD | 7 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02850406/event-totals